<DOC>
	<DOC>NCT02843204</DOC>
	<brief_summary>The aim of this study is the safety and efficacy of anti-PD-L1 plus NK immunotherapy to multiple solid tumors.</brief_summary>
	<brief_title>Combination of Anti-PD-L1 and NK Immunotherapy for Recurrent Solid Tumors</brief_title>
	<detailed_description>By enrolling patients with solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using anti-PD-L1 and natural killer (NK) cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).</detailed_description>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence Body tumor 16, the maximum tumor length &lt; 5 cm KPS ≥ 70, lifespan &gt; 6 months Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L Patients with cardiac pacemaker Patients with brain metastasis Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>NK immunotherapy</keyword>
</DOC>